Indoco Remedies on Friday said the US Food and Drug Administration has cleared the Goa-based sterile manufacturing facility for finished dosages. The US health regulator had inspected the plant in November last year, it added.
The change in the inspection classification status from ‘Official Action Initiated’ to ‘Voluntary Action Initiated’ by the USFDA signifies that the site has come out of the warning letter issued to the site in March 2017, the drug firm said.